The General Hospital Corporation

The General Hospital Corporation, doing business as Massachusetts General Hospital's Research Management Division, is a nonprofit academic medical center and Harvard Medical School teaching hospital that functions as a prime recipient and prime contractor delivering federally funded biomedical and translational research services across the National Institutes of Health, Department of Defense, and specialty agencies. MGH competes full-and-open (no set-aside) across all award vehicles and operates primarily as a research prime rather than a subcontractor, positioning it as a major federal research performer rather than a sub-tier vendor.

MGH's federal footprint centers on investigator-initiated research grants spanning oncology, neuroscience, cardiovascular research, infectious disease, aging, precision medicine, and translational therapeutics. Recent representative work includes a $3.86 million NIH Allergy and Infectious Diseases Research award (MARVELOUS study) investigating immune responses in pregnant women receiving RSV vaccination and transfer of antibodies to infants; a $2.54 million NIH Cooperative Agreement for IND-enabling CRISPR gene therapy development for multisystem smooth muscle dysfunction syndrome; and a $1.73 million NIA grant examining cognitive impairment and Alzheimer's disease in people living with HIV in Uganda. The institution also holds a $25 million DARPA Blanket Purchase Agreement (effective August 21, 2024 through August 20, 2027) for commercial accelerator support services, clinical evaluations of emerging technologies, clinical trial protocol development, and go-to-market strategy support, with ten task orders totaling approximately $7.68 million as of June 2025. Work is performed at MGH's Research Management Division in Boston, Massachusetts, with some task orders directed to Arlington, Virginia and other locations as required.

Customer concentration reflects NIH dominance. Of 6,597 total awards (prime and sub), the top five funding agencies account for over 50% of awards: National Institute on Aging (606 awards), National Cancer Institute (578 awards, $23.2 million combined potential value), National Institute of Allergy and Infectious Diseases (477 awards), and National Institute of Neurological Disorders and Stroke (408 awards). By potential value, the National Institute on Drug Abuse leads with 127 awards and $67.5 million combined potential value; the National Heart, Lung, and Blood Institute follows with 396 awards and $48.3 million. MGH serves 124 distinct customer agencies, signaling broad federal research engagement. The combined potential value across all awards reaches $429.8 million, with obligated dollars of $12.9 billion—a ratio indicating substantial ongoing performance and multi-year funding commitments.

Activity trajectory shows recent deceleration. The five-year awards-per-year pattern (2022: 451, 2023: 521, 2024: 729, 2025: 566, 2026: 233) peaked in 2024 and declined in 2025 and 2026, likely reflecting incomplete data capture in 2026. A recompete cliff looms: 719 awards with ultimate completion in the next 24 months carry $38.7 million in combined potential value, representing significant exposure to lost or competed work.

MGH operates as a prime in 79% of recent awards and as a sub in 21%. Service Contract Inventory data (SCI-reportable contracts above the $150,000 threshold, covering FY2022–FY2024) shows modest federal service-contract invoicing: $8.8 million total across 43 SCI records (22 prime, 21 as named sub). SCI-reported FTE trajectory was 19.2 FTEs in FY2022, dropped to 2.4 in FY2023, and rose to 22.1 in FY2024. On federal services contracts captured in SCI, government-paid hourly rates ran a median of $254.28/hr, with rates from $78.73/hr (10th percentile) to $663.31/hr (90th percentile), reflecting the mix of entry-level research support and senior investigator effort. Across SCI-reportable prime contracts, subcontractors account for only 2% of total contractor hours, indicating MGH builds its own delivery teams rather than relying on subs. Two named subcontractors appear in SCI records: Bridgewood Research Solutions LLC (for DARPA commercial accelerator support work) and various sub-recipients on NIH grants.

Federal grant subrecipient footprint is extensive. MGH functions as a sub-recipient on grants where it provides specialized research services—clinical trial enrollment and coordination, biospecimen collection, neuroimaging analysis, immunological characterization, and data management. Notable recent sub-award relationships include University of Pittsburgh (for protein assays in airway epithelial models and neuroimaging analysis of traumatic brain injury biomarkers), Scripps Research Institute (for cryo-electron microscopy of influenza vaccine immunogens and structural validation), Yale University and Johns Hopkins University (for immunological and systems-serology analysis on maternal RSV vaccination studies), and Michigan State University (for cell transplantation methodology and tissue analysis in Alzheimer's disease cell therapy research). These arrangements position MGH as a translational research hub providing infrastructure, clinical populations, specialized imaging, and bioanalytical capabilities to prime recipients.

Corporate structure: MGH is a child entity of Partners Healthcare System Incorporated, a major academic health system with substantial NIH and federal research portfolios. The parent structure does not constrain MGH's independent competitive posture; MGH holds its own UEI, CAGE codes, and federal contracts/grants in its own name.

Award vehicles carry no set-asides. The top parent vehicles include federal IDIQs such as Indefinite Delivery Contract HHSI241201600023I (65 task orders, $3.2 million), Contract 75N92022D00014 (12 task orders, $22 million), and the DARPA Commercial Accelerators Support BPA (11 task orders, $8.2 million from HR001124A0003). These vehicles reflect MGH's role as a specialized research performer across health services, biomedical imaging, and defense research portfolios. MGH does not hold seats on government-wide GWACs; its presence on vehicles is agency-specific and award-driven.

MGH's federal strategy centers on competitive research excellence rather than set-aside or price-leadership positioning. The institution leverages Harvard Medical School affiliation, translational research infrastructure (imaging centers, biobanks, clinical trials platforms), and workforce expertise in oncology, neuroscience, and precision medicine to win NIH R01s, cooperative agreements, and DARPA task orders. Recompete exposure ($38.7 million in the next 24 months) and recent activity decline (2026 awards down from 2024 peak) signal tight competitive dynamics and the need for continuous grant renewal and new vehicle capture to sustain the research portfolio.